Ireland Rejects First-Ever Friedreich’s Drug | Cork News

Ireland’s health service is refusing to cover a groundbreaking new drug for Friedreich’s Ataxia, a rare and devastating neurological disease affecting about 200 people, due to its staggering €160 million price tag. The National Centre for Pharmacoeconomics says the cost per patient—€280,000 annually—is unsustainable, even though the drug is the first of its kind approved by the EU and FDA. Patients, devastated by the decision, are rallying and lobbying politicians in a fierce fight to gain access. Other countries like Scotland and the Netherlands face similar hurdles, highlighting a global struggle to balance life-saving innovation with healthcare affordability. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/629f98497041f4aa